The PRMT2IP Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the PRMT2IP gene in the SK-HEP-1 human hepatic adenocarcinoma cell line. This product comprises a heterogeneous mixture of cells with varying edits at the target locus, providing a robust platform for functional studies while avoiding clonal selection biases. The polyclonal format ensures representation of diverse genetic backgrounds, making it suitable for assessing phenotypic variability and for experiments where population-level responses are critical.
SK-HEP-1 cells, originally isolated from the ascitic fluid of a patient with adenocarcinoma, exhibit a distinctive dual phenotype characterized by both epithelial and endothelial-like features. These cells express endothelial adhesion molecules, form capillary-like tubes in vitro, and are widely utilized as a surrogate model for liver sinusoidal endothelial cells. Their unique properties also make them a valuable system for dissecting mechanisms of tumor angiogenesis, hepatocellular carcinoma progression, and endothelial-mesenchymal transition.
PRMT2IP (also known as WDR77 or MEP50) encodes a WD repeat-containing scaffold protein that directly interacts with the arginine methyltransferase PRMT5. As an essential cofactor, it facilitates symmetric dimethylation of arginine residues on histone H4R3 and spliceosomal Sm proteins, thereby modulating chromatin structure, transcriptional regulation, and pre-mRNA splicing. This methylation activity is integrated into cellular signaling networks through upstream activation by growth factor receptors such as EGFR and VEGFR, which signal via PI3K, AKT, mTOR, and ERK. Downstream consequences include altered activity of transcription factors like p53 and FOXO1, linking epigenetic control to key cancer-relevant pathways.
In the SK-HEP-1 context, knockout of PRMT2IP disrupts PRMT5-mediated symmetric methylation, resulting in profound changes in histone modifications and spliceosome function. This loss-of-function model enables detailed investigation of arginine methylation??s role in liver cancer biology, particularly regarding proliferation, apoptosis, and angiogenic signaling. The endothelial-like characteristics of SK-HEP-1 render this system especially valuable for studying how PRMT2IP influences vascular mimicry and tumor microenvironment interactions under physiologically relevant conditions.
Typical applications include Western blotting to confirm PRMT2IP ablation and changes in H4R3me2s, co-immunoprecipitation to verify PRMT5 complex integrity, and RT-qPCR or RNA-seq to assess global transcriptomic and splicing alterations. Functional assays such as proliferation, apoptosis, migration, and invasion studies can dissect the phenotypic consequences of gene disruption. Additionally, this model supports drug sensitivity testing with PRMT5 inhibitors and combination treatments targeting the PI3K/AKT/mTOR axis. For further technical details or to explore custom applications, please contact Ascent Research.
